ISRCTN55250367已完成3 期
Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day). Twelve-week treatment plus double-blind extension for 12 weeks.
Institut de Recherches Internationales Servier (France)0 个研究点目标入组 324 人开始时间: 2007年7月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 324
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged between 18 to 70 years (included)
- •2. Male or female
- •3. Fulfilling Diagnostic and Statistical Manual of mental disorders fourth edition (DSM-IV) criteria for major depressive disorder
排除标准
- •1. Women of childbearing potential without effective contraception as well as pregnant or breastfeeding women
- •2. All types of depression other than major depressive disorder, all other psychiatric disorders
研究者
相似试验
进行中（未招募）
1 期
Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day). Twelve-week treatment plus double-blind extension for 12 weeks.MedDRA version: 9.1 Level: LLT Classification code 10057840 Term: Major depressionMajor Depressive DisorderEUCTR2006-006540-54-GBServier Research and Development Limited300
进行中（未招募）
不适用
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.MedDRA version: 3.3Level: P.T.Classification code 10025453Major Depressive DisorderEUCTR2005-002388-95-BEInstitut de Recherches Internationales Servier400
进行中（未招募）
不适用
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.Major Depressive DisorderEUCTR2005-002388-95-PTInstitut de Recherches Internationales Servier400
进行中（未招募）
不适用
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.MedDRA version: 3.3Level: P.T.Classification code 10025453Major Depressive DisorderEUCTR2005-002388-95-HUInstitut de Recherches Internationales Servier400
进行中（未招募）
1 期
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.MedDRA version: 3.3Level: P.T.Classification code 10025453Major Depressive DisorderEUCTR2005-002388-95-ESaboratorios Servier S.L. (For Spain only)400